Clinical trial / 2012
Water-dispersible hesperetin was rapidly absorbed and improved peripheral vasodilatation in women.
In a human trial involving women with cold sensitivity, an oral dose of 150 mg micronized hesperetin was rapidly absorbed, reaching a maximum concentration of 10.2 ± 1.2 μM within 1 hour. This single dose proved effective at enhancing peripheral vasodilatation. Complementary cell experiments showed its conjugated metabolite promoted endothelial nitric oxide production through inhibition of NADPH oxidase activity.
- Study type
- Clinical trial with in vitro study
- Who was studied
- Adult women with cold sensitivity
- What was measured
- Bioavailability and peripheral vasodilatation
THE PAPER
Bioavailability of orally administered water-dispersible hesperetin and its effect on peripheral vasodilatation in human subjects: implication of endothelial functions of plasma conjugated metabolites.
Takumi H, Nakamura H, Simizu T, Harada R, Kometani T, Nadamoto T, Mukai R, Murota K, Kawai Y, Terao J. Food Funct, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.